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Background: To conduct a systematic review and network meta-analysis of randomized controlled trials (RCTs) with
the aims of comparing relevant clinical outcomes (that is, visual analog scores (VAS), total and sub-Western Ontario
and McMaster Universities Osteoarthritis index (WOMAC) scores, Lequesne algofunctional index, joint space width
change, and adverse events) between diacerein, glucosamine, and placebo.
Methods: Medline and Scopus databases were searched from inception to 29 August 2014, using PubMed and
Scopus search engines and included RCTs or quasi-experimental designs comparing clinical outcomes between
treatments. Data were extracted from original studies. A network meta-analysis was performed by applying weight
regression for continuous outcomes and a mixed-effect Poisson regression for dichotomous outcomes.
Results: Thirty-one of 505 identified studies were eligible. Compared to placebo, glucosamine showed a significant
improvement with unstandardized mean differences (UMD) in total WOMAC, pain WOMAC, function WOMAC,
and Lequesne score of −2.49 (95% confidence interval (CI) −4.14, −0.83), −0.75 (95% CI: −1.18, −0.32), −4.78
(95% CI: −5.96, −3.59), and −1.03 (95% CI: −1.34, −0.72), respectively. Diacerein clinically improves visual analog
scores, function WOMAC, and stiffness WOMAC with UMD values of −2.23 (95% CI: −2.82, −1.64), −6.64 (95%
CI: −10.50, −2.78), and −0.68 (95% CI: −1.20, −0.16) when compared to placebo.
Conclusions: The network meta-analysis suggests that diacerein and glucosamine are equally efficacious for symptom
relief in knee OA, but that the former has more side effects.
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Osteoarthritis (OA) is the most common chronic joint dis-
ease of the older patient. The primarily affected joints are
the knee and hip. The progression of the disease is influen-
tial on quality of life. This included functional and social
activities, body image, and emotional well-being. In
non-operative treatment, pain reduction and improved
function are the primary goals. Management of mild
degree OA of the knee mainly consists of medical treat-
ment and lifestyle modifications. Non-steroidal anti-* Correspondence: Jatupon_kong@hotmail.com
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article, unless otherwise stated.inflammatory drugs (NSAIDs) are the most commonly
prescribed agents for pain management, but they in-
crease the risk of gastrointestinal (GI) bleeding and vas-
cular adverse events [1,2]. Therefore, second-line drugs
such as symptomatic slow-acting drugs for OA (SYSA-
DOA) which include glucosamine sulfate, glucosamine
hydrochloride, chondroitin sulfate, hyaluronic acid, av-
ocado soybean unsaponifiables (ASU), and diacerein
are more commonly used. These drugs may improve
patient symptoms as well as reduce cartilage degradation
[3,4], also having decreased occurrence of GI adverse
events when compared to NSAIDs. Two drugs are recom-
mended by the European League Against Rheumatism
guidelines 2003. These include an interleukin-1 (IL-1B) in-
hibitor (diacerein) and glucosamine. However, these drugsd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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diacerein and glucosamine groups have the greatest
amount of randomized controlled trial (RCT) studies
and meta-analysis when compared to all other SYSA-
DOA. The results of all the studies show that diacerein
and glucosamine improve symptoms and decrease
structural progression in OA of the knee when com-
pared to NSAIDs and placebo. Previous systematic re-
views [3-6] have shown that diacerein had higher
efficacy in reducing pain and Lequesne index, but in-
creased risk of diarrhea when compared to placebo
[4,6]. Similar effects were observed in systematic re-
views of the efficacy of glucosamine, which showed a
significant reduction in pain when compared to pla-
cebo but no effect on minimal joint space narrowing
or adverse events [3,5]. However, no RCTs directly
compared the clinical efficacy and safety of diacerein
with glucosamine. We therefore conducted a system-
atic review with a network meta-analysis of RCTs with
the aim of comparing relevant clinical outcomes (that
is, visual analog score, Western Ontario and McMaster
Universities Osteoarthritis index (WOMAC) score,
Lequesne algofunctional index, joint space width
change, and adverse events) between diacerein, glu-
cosamine, NSAIDs, and placebo. The main outcomes
that were focused on in this study included pain, func-
tional assessment, joint space width change, and safety
issues of the medications.Methods
Search strategy
The Medline and Scopus databases were used to identify
relevant studies published in English from the date of in-
ception to 29 August 2014. The PubMed and Scopus
search engines were used to locate studies using the fol-
lowing search terms: (osteoarthritis, degenerative arth-
ritis, adult, older person), (symptomatic slow acting drug
for osteoarthritis; SYSADOA, diacerein, glucosamine),
(pain, function, score, grade, WOMAC, Knee Society
Score (KSS), motion, radiographic grading, X-ray, MRI,
Kellgren-Lawrence), (clinical trial, RCT, randomized
controlled trial). Search strategies for Medline and Sco-
pus are described in Additional file 1. Relevant studies
from the reference lists of identified studies and previous
systematic reviews were also explored.Selection of studies
Identified studies were selected by one author (J.K.) and
randomly checked by A.T. Titles and abstracts were ini-
tially screened; full papers were then retrieved if a deci-
sion could not be made from the abstracts. The reasons
for ineligibility or exclusion of studies were recorded
and described (Figure 1).Inclusion criteria
Randomized controlled trials or quasi-experimental de-
signs comparing clinical outcomes between treatments
in primary OA patients’ knee were eligible if they met
the following criteria:
– Compared clinical outcomes between glucosamine
(either glucosamine sulfate or glucosamine
hydrochloride) and diacerein, or each of these
treatments with other comparators (for example,
placebo, non-steroidal anti-inflammatory drugs).
– Compared at least one of the following outcomes:
pain score, function, patient/physician global
assessments, range of motion, joint space width
difference, and adverse events.
– Had sufficient data to extract and pool: reported
mean, standard deviation (SD), numbers of subjects
according to treatments for continuous outcomes,
and number of patients according to treatment for
dichotomous outcomes.
Data extraction
Two reviewers (J.K. and T.A.) independently performed
data extraction using standardized data extraction forms.
General characteristics of the study (mean age, gender,
body mass index, duration of OA, pain score, and func-
tional scores at baseline) were extracted. The number of
subjects, mean, and SD of continuous outcomes (pain by
visual analog score (VAS), total and sub-WOMAC
scores, and Lequesne algofunctional index) between the
groups were extracted. Cross-tabulated frequencies be-
tween treatments and adverse events were also ex-
tracted. Any disagreements were resolved by discussion
and consensus with a third party (A.T.).
Risk of bias assessment
Two authors (J.K. and T.A.) independently assessed risk
of bias for each study. Six study quality domains were
considered, including sequence generation, allocation
concealment, blinding (participant, personnel, and out-
come assessors), incomplete outcome data, selective
outcome reporting, and other sources of bias [7]. Dis-
agreements between two authors were resolved by con-
sensus and discussion with a third party (A.T.).
Outcomes
The outcome of interests were pain VAS, total and sub-
WOMAC scores (pain, stiffness, and function), Lequesne
algofunctional index, joint space width (minimum), and
adverse events. Methods of measure for these outcomes
were used according to the original studies. Briefly, this
includes the VAS pain scale from 0 to 10; the WOMAC
score that consists of pain (0 to 20), stiffness (0 to 8),
and function (0 to 68) with total scores of 0 to 96 [8].
Figure 1 Flow of study selection.
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10), maximum distance walked (0 to 6), and activities of
daily living (0 to 8) with total scores of 0 to 24 [9,8]. For
joint space width change, lower values of these scores
refer to better outcomes. Adverse events were consid-
ered as composite and separate outcomes of the follow-
ing: a musculoskeletal disorder, respiratory disorder,
genitourinary tract disorder or central nervous system
disorder, and GI adverse effects.Statistical analysis
Direct comparisons of continuous outcomes were mea-
sured at the end of each study between glucosamine ver-
sus placebo and diacerein versus placebo and were then
pooled using an unstandardized mean difference (UMD).
Heterogeneity of the mean difference across studies was
checked using the Q statistic, and the degree was quanti-
fied using the I2 statistic. If heterogeneity was present (P
value <0.10 or the I2 > 25%), the UMD was estimated
using a random effects model; otherwise, a fixed-effects
model was applied.
For dichotomous outcomes, a relative risk (RR) of ad-
verse reactions of treatment comparisons at the end of
each study was estimated and pooled. Heterogeneity was
assessed using the same method as mentioned previously.
If heterogeneity was present, the DerSimonian and Laird
method [10] was applied for pooling; otherwise, the fixed-
effects model by inverse variance method was applied.
Meta-regression was applied to explore the source of het-
erogeneity (for example, mean age, percentage of females,
bone mass index (BMI), Kellgren-Lawrence grading, dur-
ation of OA) if data was available. Publication bias was
assessed using contour-enhanced funnel plots [11,12] and
Egger tests [13].
For indirect comparisons, network meta-analyses
were applied to assess all possible effects of treatment
measured at different times if summary data were
available for pooling [14-16]. A linear regression
model weighted by inverse variance was applied to as-
sess the treatment effects with adjustment for study
effects and time for continuous outcomes. For adverse
events, a mixed-effect Poisson regression was applied
to assess treatment effects [15]. Summary data was ex-
panded to individual patient data using the “expand”
command in STATA. Treatment was considered as a
fixed-effect, whereas the study variable was considered
as a random-effect in a mixed-effect model. The
pooled RR and its 95% confidence intervals (CIs) were
estimated by exponential coefficients of treatments.
All analyses were performed using STATA version
12.0 [17]. A P value <0.05 was considered statistically
significant, except for the test of heterogeneity where
P value < 0.10 was used.Results
Among 505 identified studies and 2 referred studies, 31
studies [18-48] were eligible for data extraction. Rea-
sons for ineligibility are described in Figure 1. Charac-
teristics of the 31 studies [18-44,46-48,45] are described
in Table 1.
Among 23 glucosamine studies [26-44,1-4], the com-
parators included placebo, NSAIDs, and both placebo
and NSAIDS in 17 studies [39,30,29,33,43,31,42,41,32
,38,26,27,35,37,4,1,2], 4 studies [40,36,34,48,28], and 2
studies [28,44], respectively. All studies used glucosamine
sulfate, except for one study [31] which used glucosamine
hydrochloride. Among eight diacerein studies, five studies
[21,23,19,22,18], two studies [25,20], and 1 study [21] had
comparators as placebo, NSAIDs, and both NSAIDs and
placebo, respectively. Most studies (24/27) included OA
of the knee and the rest were OA of the hip. Mean age,
body mass index (BMI), and duration of OA varied
from 42 to 69 years, 24.0 to 32.6 kg/m2, and 1.6 to
13 years, respectively. Percentage of females in each
study ranged from 5.1% to 88%. Duration of treatment
ranged from 4 weeks to 3 years. Various outcomes were
compared between the treatment groups (Figure 1).
Risk of bias in included studies
Risk of bias assessment is described in Additional file 2.
Direct comparisons
Data used for direct comparisons for all treatments and
outcomes were measured at the end of each study, as
described in Table 1. Pooling according to outcomes was
performed if there were at least two studies for each
comparison, as clearly described below.
Visual analog score
Among eight studies [25,39,34,21,23,40,42,47], five stud-
ies compared glucosamine pain VAS with comparators
of placebo [39,42,2] and NSAIDs [34,40], respectively.
Three studies compared diacerein with placebo [21,23]
and NSAIDs [25]. Most studies assessed pain using the
VAS at 4 weeks to 3 years. Data for the mean and SD
of VAS scores are described in Additional file 3. The
mean VAS was −0.90 (95% CI: −1.67, −0.14) units signifi-
cantly lower in glucosamine than in NSAIDs (Table 2).
The mean VAS score was about −1.44 (95% CI: −3.01,
0.12) units lower in glucosamine than in placebo, but
this was not significant. The pooled effects of diacerein
versus placebo from three studies (n = 103 vs. 98) dis-
played no heterogeneity (I2 = 0%) with an UMD of −2.23
(95% CI: −2.82, −1.64). The effect of diacerein versus
NSAIDs was not statistically different with an UMD of
0.149 (95% CI: −0.29, 0.59). There was no evidence of
publication bias for both pooled effect estimates.
Table 1 Characteristics of included studies





Pujalte JM 1980 8 weeks GS (1,500) Placebo 61.7 85 - - VAS, AR
Lopes VA 1982 8 weeks GS (1,500) NSAIDs 56.4 74 - 3.2 VAS, AR
Muller FH 1994 4 weeks GS (1,500) NSAIDs 54 42.3 - 4.8 Lequesne, AR
Noack W 1994 4 weeks GS (1,500) Placebo 55 60.3 - - Lequesne, AR
Nguyen M 1994 8 weeks D (50) NSAIDs, placebo 62 62.7 - 5.25 VAS, Lequesne, AR
Qiu GX 1998 4 weeks GS (1,500) NSAIDs 56.4 79 - - VAS, AR
Houpt JB 1999 8 weeks GH (1,500) Placebo 64.5 64.4 - 8.3 WOMAC, AR
Rindone JP 2000 4, 8 weeks GS (1,500) Placebo 63.5 5.1 - 13 VAS, AR
Pelletier JP 2000 24 weeks D (50, 100, 150) Placebo 62.8 76 31.28 7.9 VAS
Reginster JY 2001 3 years GS (1,500) Placebo 65.8 79.4 27.35 7.8 WOMAC, JSW, AR
Dougados M 2001 3 years D (100) Placebo 62.6 84 - - Lequesne, JSW
Hughes R 2002 6 months GS (1,500) Placebo 62.3 68 - 7.63 AR
Pavelka K 2002 1, 2, 3 years GS (1,500) Placebo 62.4 78.5 25.7 10.55 Lequesne, JSW, AR
Braham R 2003 3 months GS (2,000) Placebo 42.2 28.3 - 12.97 AR
Cibere J 2004 24 weeks GS (1,500) Placebo 64.5 57.7 25.26 1.6 AR
McAlindon T 2004 12 weeks GS (1,500) Placebo - 64 32.57 - WOMAC, AR
Pham T 2004 1 year D (100) Placebo 64.7 65.3 29.6 - Lequesne
Clegg DO 2006 24 weeks GS (1,500) Placebo, NSAIDs 58.7 42.2 31.73 10 WOMAC, AR
Zheng WJ 2006 12, 16 weeks D (100) NSAIDs 56.2 66.2 26.13 7.23 VAS, WOMAC, AR
Herrero-Beaumont G 2007 24 weeks GS (1,500) Placebo 63.9 88 27.65 7.31 Lequesne, AR
Louthrenoo W 2007 12, 24 weeks D (50) NSAIDs 54 73 26.85 3.58 WOMAC
Pavelka K 2007 12, 24 weeks D (50) Placebo 63.7 65.5 28.9 6.497 WOMAC, AR
Frestedt JL 2008 12 weeks GS (1,500) Placebo 59.1 60 32.24 - WOMAC, AR
Kawasaki T 2008 18 weeks GS (1,500) Placebo 68.9 - 23.95 - JSW
Rozendaal RM 2008 3, 12, 24 months GS (1,500) Placebo 63.4 69.4 27.95 - JSW, AR
Sawitzke AD 2008 2 months GS (1,500) Placebo, NSAIDs 50.6 55.7 - 8.52 JSW
Brahmachari B 2009 12 weeks D (50) Placebo 49.1 83.6 24.66 2.76 VAS, WOMAC, AR
Madhu K 2013 6 weeks GS (1,500) Placebo 56.8 70 27.9 - VAS, AR
Chopra A 2013 24 weeks GS (1,500) NSAIDs 55.5 - 27.7 - WOMAC, AR
Durmus D 2013 12 weeks GS (1,500) Placebo 55.8 - 27.7 - WOMAC
Kwoh CK 2014 24 weeks GS (1,500) Placebo 52.24 48.9 28.9 - WOMAC, AR
AR = adverse event, BMI = body mass index, D = diacerein, GH = glucosamine hydrochloride, GS = glucosamine sulfate, JSW = joint space width, VAS = visual
analog score.
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As described in Table 2, the total WOMAC scores were
compared as change from baseline and the actual scores
measured at the end of each study. Among six studies
[38,27,35,30,29,33] with total WOMAC score changes,
the effects displayed no heterogeneity (I2 = 0%) with an
UMD of −2.49 (95% CI: −4.14, −0.83). The actual total
WOMAC scores from two studies [31,29] were not statis-
tically significant with an UMD of 5.67 (95% CI: −11.26,
22.61). The actual total WOMAC scores and change in
sub-WOMAC scores (pain, stiffness, and function) were
also compared (Table 2). Compared with placebo,glucosamine resulted in a significantly greater change
in WOMAC pain scores with an UMD of −0.75 (95%
CI: −1.18, −0.32). In addition, mean functional and
stiffness WOMAC scores were significantly lower in
the diacerein groups when compared to the NSAIDs
and placebo groups (6.64 (95% CI: −10.50, −2.78)
and −0.68 (95% CI: −1.20, −0.16)).
Lequesne score and joint space width
Only glucosamine resulted in a significantly greater
change of Lequesne score when compared to placebo
(UMD= −1.030 (95% CI: −1.34, −0.72)) (Table 2).
Table 2 Summarized results of direct comparisons according to type of interventions
Clinical outcomes No. studies I2 No. subjects UMD (95% CI)
VAS
Glu vs. Pla 3 83.4 89 vs. 89 −1.44 (−3.01, 0.12)
Glu vs. NSAIDs 2 0 106 vs. 110 −0.90 (−1.67, −0.14)*
Dia vs. Pla 2 0 103 vs. 98 −2.23 (−2.82, −1.64)*
Dia vs. NSAIDs 2 0 181 vs. 182 0.15 (−0.29, 0.59)
Total WOMAC score change
Glu vs. Pla 6 0 437 vs. 423 −2.49 (−4.14, −0.83)*
Actual score
Glu vs. Pla 2 79.8 73 vs. 76 5.67 (−11.26, 22.61)
Pain WOMAC score change
Glu vs. Pla 10 66.3 1,069 vs. 1,056 −0.75 (−1.18, −0.32)*
Glu vs. NSAIDs 2 85.5 425 vs. 423 −0.07 (−1.5, 1.36)
Actual score
Glu vs. Pla 4 81 408 vs. 418 0.06 (−1.33, 1.45)
Functional WOMAC score change
Glu vs. Pla 10 67.6 1,069 vs. 1,056 −0.58 (−1.98, 0.81)
Glu vs. NSAIDs 2 77.1 425 vs. 423 −0.84 (−2.95, 4.63)
Actual score
Glu vs. Pla 4 90.5 408 vs. 418 −4.78 (−5.96, −3.59)*
Dia vs. Pla 2 0 110 vs. 110 −7.72 (−18.83, 3.39)
Dia vs. NSAIDs 2 92.9 189 vs. 185 −6.64 (−10.50, −2.78)*
Stiffness WOMAC score change
Glu vs. Pla 7 68.1 759 vs. 743 −0.02 (−0.06, 0.03)
Actual score
Glu vs. Pla 3 31.5 390 vs. 389 0.09 (−0.38, 0.56)
Dia vs. Pla 2 1 110 vs. 110 −0.68 ( −1.20, −0.16)*
Lequesne score scores change
Glu vs. Pla 2 87.7 207 vs. 205 −1.03 (−1.34, −0.72) *
Dia vs. Pla 2 0 340 vs. 337 0.002 (−0.704, 0.708)
Joint space width
Glu vs. Pla 4 86.4 357 vs. 350 0.008 (−0.232, 0.248)
All adverse events RR (95% CI)
Glu vs. Pla 16 7.3 1,366 vs. 1,365 1.12 (1.02, 1.23)*
Glu vs. NSAIDs 5 81.9 631 vs. 632 0.53 (0.24, 1.20)
Dia vs. Pla 4 76.6 275 vs. 278 5.58 ( 2.14, 14.59)*
Dia vs. NSAIDs 2 97.6 181 vs. 182 1.59 ( 0.47, 5.44)
GI adverse event
Glu vs. Pla 14 0 1,217 vs. 1,211 0.99 ( 0.82, 1.19)
Glu vs. NSAIDs 5 74.3 631 vs. 632 0.51 ( 0.22, 1.20)
Dia vs. Pla 6 94.9 937 vs. 701 2.00 ( 0.69, 5.74)
Dia vs. NSAIDs 3 86.6 373 vs. 267 1.37 ( 0.89, 2.10)
*Statistically significant difference (P < 0.05). CI = confidence interval, NSAIDs = non-steroidal anti-inflammatory drugs, RR = relative risk, UMD = unstandardized
mean difference, VAS = visual analog score, WOMAC =Western Ontario and McMaster Universities Osteoarthritis index.
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Table 3 Comparisons of treatment effects: a network
meta-analysis
Treatment N Β P value 95% CI
Pain VAS score
Glucosamine 195 −1.75 0.034* −3.32, −0.17
NSAIDs 292 −1.74 0.047* −3.44, −0.03
Diacerein 209 −1.78 0.024* −3.24, −0.32
Placebo 187 0 - -
Diacerein vs. glucosamine - −0.03 0.964 −1.58, 1.52
NSAIDs vs. glucosamine - 0.01 0.988 −1.52, 1.54
Diacerein vs. NSAIDs - −0.04 0.893 −0.72, 0.64
Total WOMAC score
Glucosamine 73 17.70 0.367 −35.46, 70.87
NSAIDs 79 −7.03 0.334 −26.51, 12.45
Diacerein 164 −6.2 0.597 −39.69, 27.29
Placebo 159 0 - -
Diacerein vs. glucosamine - −23.90 0.218 −72.85, 25.06
NSAIDs vs. glucosamine - −24.74 0.180 −69.91, 20.44
Diacerein vs. NSAIDs - 0.84 0.899 −18.52, 20.20
Pain WOMAC score
Glucosamine 408 1.47 0.139 −0.74, 3.68
NSAIDs 164 −0.38 0.612 −2.31, 1.55
Diacerein 397 −0.75 0.521 −3.75, 2.24
Placebo 491 0 - -
Diacerein vs. glucosamine - −2.22 0.078 −4.84, 0.39
NSAIDs vs. glucosamine - −1.85 0.065 −3.88, 0.18
Diacerein vs. NSAIDs - −0.376 0.643 −2.46, 1.71
Function WOMAC score
Glucosamine 408 −2.42 0.534 −11.18, 6.33
NSAIDs 503 1.53 0.463 −3.13, 6.20
Diacerein 189 1.89 0.392 −3.02, 6.81
Placebo 407 0 - -
Diacerein vs. glucosamine - 4.32 0.436 −8.03, 16.67
NSAIDs vs. glucosamine - 3.96 0.438 −7.43, 15.34
Diacerein vs. NSAIDs - 0.36 0.913 −7.16, 7.89
Stiffness WOMAC score
Glucosamine 390 −0.15 0.480 −0.66, 0.36
NSAIDs 397 −0.77 0.207 −2.14, 0.60
Diacerein 196 −0.89 0.097 −2.01, 0.23
Placebo 499 0 - -
Diacerein vs. glucosamine - −0.74 0.193 2.00, −0.52
NSAIDs vs. glucosamine - 0.62 0.205 −1.71, 0.47
Diacerein vs. NSAIDs - −0.12 0.788 −1.20, 0.96
Lequesne score change
Glucosamine 214 −1.12 0.063 −2.36, 0.12
Diacerein 75 0.03 0.970 −2.13, 2.18
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change in joint space when compared to placebo with an
UMD of 0.008 (95% CI: −0.232, 0.248).
Adverse events
Compared with a placebo control, composite adverse
events were 1.12 (95% CI: 1.02, 1.23) and 5.58 (95% CI:
2.14, 14.59) times significantly higher in glucosamine
and diacerein than in placebo (Table 2). When consider-
ing only GI adverse events, the pooled RR of glucosa-
mine was 0.99 (95% CI: 0.82, 1.19) when compared with
placebo and 0.393 (95% CI: 0.157, 0.588) when com-
pared with NSAIDs. Conversely, diacerein respectively
had 2.00 (95% CI: 0.69, 5.74) and 1.37 (95% CI: 0.89,
2.10) times more GI effects than placebo and NSAIDs,
but this data was not statistically significant.
Network meta-analysis
Visual analog score
Data from eight studies [39,34,40,42,21,23,25,2] were
included in pooling of indirect comparisons of the
VAS scores (Additional file 4). Mean VAS scores mea-
sured at 4 to 24 weeks after receiving treatments were
fitted as the dependent variable in a mixed linear re-
gression model.
The VAS score was lowest in the diacerein group with
an overall mean of 3.28 (95% CI: 2.25, 4.30) followed by
the glucosamine (3.30, 95% CI: 2.61, 4.01), NSAIDs
(3.31, 95% CI: 2.13, 4.50), and placebo groups (5.05, 95%
CI: 3.79, 6.32). The regression analysis suggested that all
active treatments resulted in a significant difference in
VAS score when compared to placebo (Table 3). Mul-
tiple comparisons suggested no difference in effects be-
tween active treatments (Figure 2).
Total WOMAC score
Data from four studies [31,29,20,22] were included in
pooling of indirect comparisons of the actual total
WOMAC scores (Additional file 4). The mean total
WOMAC scores were lower in the diacerein and NSAID
groups, but higher in glucosamine compared to placebo,
but this was not statistically significant (Table 3). Mul-
tiple comparisons suggested no difference in effects be-
tween active treatments.
Pain WOMAC score
Data from six studies [31,28,29,20,22,4] were included in
the network meta-analysis of pain WOMAC scores
(Additional file 4). Fitting the regression analysis using
placebo as the reference suggested that pain WOMAC
scores were lower in both the diacerein and NSAIDs
groups. In contrast, the pain score was higher in the glu-
cosamine group compared with placebo, but this was
not statistically significant (Table 3).
Table 3 Comparisons of treatment effects: a network
meta-analysis (Continued)
Placebo 192 0 - -
Diacerein vs. glucosamine - 1.15 0.331 −4.32, 2.01
Joint space width change
Glucosamine 357 −0.08 0.363 −0.31, 0.14
Diacerein 246 0.12 0.207 −0.10, 0.34
Placebo 597 0 - -
Diacerein vs. glucosamine - −0.20 0.001* −0.27, −0.14
Adverse event N RR P value 95% CI
Glucosamine 1,474 1.07 0.398 0.92, 1.23
NSAIDs 814 2.20 <0.001* 1.56, 3.11
Diacerein 381 1.91 <0.001* 1.36, 2.69
Placebo 1,634 1 - -
Diacerein vs. glucosamine - 1.80 0.001* 1.27, 2.55
NSAIDs vs. glucosamine - 2.07 <0.001* 1.47, 2.91
Diacerein vs. NSAIDs - 0.87 0.416 0.62, 1.22
Adverse event (GI)
Glucosamine 1,850 0.84 0.103 0.68, 1.04
NSAIDs 899 1.33 0.038* 1.02, 1.77
Diacerein 1,345 1.44 <0.001* 1.24, 1.68
Placebo 1,917 1 - -
Diacerein vs. glucosamine - 1.72 <0.001* 1.34, 2.22
NSAIDs vs. glucosamine - 1.60 0.004* 1.16, 2.19
Diacerein vs. NSAIDs - 1.08 0.576 0.98, 1.50
*Statistically significant difference (P < 0.05). CI = confidence interval,
GI = gastrointestinal, NSAIDs = non-steroidal anti-inflammatory drugs,
RR = relative risk, VAS = visual analog score, WOMAC =Western Ontario















Figure 2 Network meta-analysis of treatment effect on VAS.
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Data from eight studies [20,22,18,31,28,29,4,25] were in-
cluded in pooling of indirect comparisons of WOMAC
function scores (Additional file 4). The regression ana-
lysis suggested that mean WOMAC function scores of
diacerein, NSAIDs, and glucosamine were lower than
placebo, but these results were not statistically signifi-
cant (Table 3). Multiple comparisons indicated that dia-
cerein and NSAIDs resulted in lower scores than
glucosamine, but these results also were not statistically
significant.
Stiffness WOMAC score
Data from six studies [20,22,18,31,28,29] were included
in pooling of indirect comparisons of the WOMAC stiff-
ness scores (Additional file 4). The regression analysis
suggested that mean WOMAC stiffness scores were
lower in diacerein, NSAIDs, and glucosamine groups
when compared to placebo (Table 3). There was no sig-
nificant difference between the three active treatments.
Lequesne algofunctional score change
Three studies [21,36,37] compared mean changes of
Lequesne scores after receiving treatments at 4 to 24 weeks
(Additional file 4). The regression analysis suggested that
mean Lequesne change in the glucosamine group was
lower than the placebo group. There was no significant
difference between the glucosamine and diacerein groups.
Joint space width difference
Data from five studies [33,38,43,41,19] were used for the
network meta-analysis of joint space width change.
Change of joint space width after receiving glucosamine
and diacerein had no statistically significant difference
when compared to placebo (Table 3). Multiple compari-
sons indicated that diacerein was superior to glucosa-
mine at −0.2 mm (95% CI: −0.27, −0.14).
Adverse events
Sixteen studies [39,37,31,42,41,32,38,26,27,35,28,30,29
,43,47,48] reported overall adverse events between
treatment groups (Additional file 5). Compared to glu-
cosamine, NSAIDs was 2.07 (95% CI: 1.47, 2.91) times
and diacerein was 1.80 (95% CI: 1.27, 2.55) times more
likely to have adverse events (Figure 3). Diacerein had
approximately 13% (RR = 0.87; 95% CI: 0.62, 1.22) lower
risk than NSAIDs, but this was not statistically signifi-
cant (Table 3). Considering only GI adverse events
showed similar results to overall adverse events.
Discussion
This review compared effects of glucosamine, diacerein,
NSAIDs, and placebo for the treatment of osteoarthritis















Figure 3 Network meta-analysis of treatment effect on drug
adverse effect.
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joint space width, and adverse events.
The second-line drugs for OA knee in the SYSADOA
group include glucosamine sulfate, glucosamine hydro-
chloride, chondroitin sulfate, hyaluronic acid, ASU, and
diacerein. This study included both glucosamine sulfate
and glucosamine hydrochloride because the results of
previous meta-analysis of both preparations show that
they have no statistically significant difference [49].
Chondroitin sulfate [50-52], hyaluronic acid [53], and
ASU [54] were not included in this review because
there were too few studies to pooled outcomes with
network meta-analysis.
The clinical results of our study were consistent to pre-
vious meta-analyses [6,4,5,3] in which glucosamine and
diacerein statistically improved pain scores (VAS and
WOMAC) and function scores (WOMAC) when com-
pared to placebo. However, we have added more evidence
of multiple active treatment comparisons. There were no
statistically significant differences between the three
groups in pain VAS, total WOMAC, sub-WOMAC
scores, and Lequesne functional scores. Although glucosa-
mine showed greater improvement in joint space width
when compared to diacerein, glucosamine and diacerein
did not show a clinically relevant effect in joint space nar-
rowing when compared to placebo. Both glucosamine and
diacerein increased risk of adverse events when compared
with placebo. However, glucosamine had a lower risk of
adverse events when compared to diacerein. In the sub-
group of gastrointestinal adverse events, patients who
took diacerein had an approximately 86.9% and 99.6%increased risk of GI adverse events when compared to
glucosamine and placebo, respectively. Glucosamine
and diacerein can reduce pain VAS and improve func-
tion (WOMAC). Glucosamine and diacerein showed no
differences in adverse effects when compared to NSAIDs.
In conclusion, this study demonstrated that either glu-
cosamine or diacerein can be selected for the treatment of
pain associated with knee osteoarthritis. Diacerein has a
higher risk of adverse GI events when compared to glu-
cosamine. Both glucosamine and diacerein cannot de-
crease risk of adverse effects, and they both do not have a
clinically relevant effect in delaying progression of joint
space narrowing in OA of the knee.
The small number of studies that evaluated each par-
ticular pair of treatments limits performing a direct
meta-analysis. A network meta-analysis circumvents this
problem by creating indirect comparisons between active
treatments that can identify the most effective therapy.
In this case, diacerein was the best therapy for improve-
ment of pain VAS scores. Glucosamine is the best ther-
apy in terms of having less adverse effects when
compared to diacerein but not when compared to pla-
cebo controls. None of the RCTs had compared com-
bined treatments with an active control.
The strengths of this study were that a network meta-
analysis was applied to increase the power of the tests and
reduce type I errors [14-16]. We applied a regression
model taking into account study effects to assess treat-
ment effects. The network meta-analysis “borrows” treat-
ment information from other studies and increases the
total sample size. As a result, treatment effects that could
not be detected in direct meta-analysis could be identified.
All possible treatment comparisons are mapped and dis-
played (Additional file 6). Although our pooled estimates
were heterogeneous, the regression model with cluster ef-
fect takes into account variations at the study level.
None of RCTs compared dual therapy with monother-
apy of SYSADOA. In relation to the SYSADOA mechan-
ism, diacerein inhibits IL-1b effects and reduces synthesis
of cartilage-specific macromolecules. In addition, dia-
cerein also decreases IL-1b-stimulated secretion of me-
talloproteinases and aggrecanases, thereby preventing
breakdown of cartilage by these enzymes [55]. Glucosa-
mine, an amino sugar, is a building block of the glycos-
aminoglycan, which is a part of the cartilage structure.
The SYSADOA group should be able to support effects
of each other and may yield better clinical improvement
than monotherapy. Further RCTs that compare dual vs.
monotherapy SYSADOA are necessary to determine if
this may enhance treatment effects.
Conclusions
This investigation demonstrates the potency of diacerein
and glucosamine in the treatment of osteoarthritis of the
Kongtharvonskul et al. European Journal of Medical Research  (2015) 20:24 Page 10 of 11knee. Glucosamine shows significant improvements in
pain score but does not decrease risk of adverse effects
and does not have a clinically relevant effect in slowing
progression of joint space narrowing in OA knee. Dia-
cerein has a higher risk of adverse GI events when com-
pared to glucosamine. Diacerein also does not decrease
risk of adverse effects and has no clinically relevant ef-
fect in delaying progression of joint space narrowing in
OA of the knee. When compared to diacerein, glucosa-
mine is the better treatment choice for OA of the knee.
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